Wells Fargo & Company Bio Cardia, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Bio Cardia, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 109 shares of BCDA stock, worth $317. This represents 0.0% of its overall portfolio holdings.
Number of Shares
109
Previous 98
11.22%
Holding current value
$317
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding BCDA
# of Institutions
24Shares Held
1.95MCall Options Held
17.2KPut Options Held
0-
Cm Management, LLC700KShares$2.04 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA651KShares$1.89 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA156KShares$453,5490.0% of portfolio
-
Two Sigma Securities, LLC New York, NY111KShares$323,2390.0% of portfolio
-
Family Management Corp New York, NY77.5KShares$225,5250.01% of portfolio
About BioCardia, Inc.
- Ticker BCDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,758,200
- Market Cap $51.7M
- Description
- BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...